Skip to main content
OpenTrials
Completed

NCT Number: NCT03359577

Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis

The main objective of this study is to establish the efficacy and safety of Psorax35 supplementation in patients with mild to moderate Psoriasis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Vulgaris Cardiovascular Diseases Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Haukeland Universitetssjukehus

Bergen, 5021, Norway

About this study

Psoriasis is a common, genetically predisposed, inflammatory and proliferative disease of the skin, the most characteristic lesions consisting of chronic, sharply demarcated, dull-red scaly plaques, particularly on extensor parts of limbs and in the scalp. Psoriasis can be divided into mild, moderate or severe psoriasis based on the extent of the skin changes

Psorax35, which is extracted from herring roe are shown to improve the condition of people with psoriasis.

The objective of this study is to investigate the effect, safety, and mechanism of action of Psorax35 on mild to moderate Psoriasis and comorbidities associated with psoriasis through a 32-weeks study.

The participants will be randomized into one of two arms; Psorax35 and Placebo. The study will include a total of 6 treatment visits involving Blood samples, Photo documentation, Psoriasis and Severity index (PASI), Body surface area (BSA), Physician's Static Global Assessment (PSGA), Life quality index (EQ-5D, VAS and DLQI), Blood pressure, Blood rate, Body Mass Index (BMI), Waist circumference, Waist/hip ratio, and 24 hrs dietary recall. At visit 4 Blood samples, Blood pressure, Blood rate, BMI, Waist circumference, Waist/hip ratio, and 24 hrs dietary recall are not included.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female and male subjects at least 18 years old understanding Norwegian oral and written information
  • Diagnosis of mild to moderate psoriasis vulgaris for at least 6 months prior to mild to moderate Psoriasis vulgaris as defined at screening by:
  • PASI scores less than 10 (mild psoriasis) and
  • Body surface area affected by chronic plaque psoriasis 1%-9.9% (mild and moderate psoriasis)
  • Women of childbearing potential must have a negative serum pregnancy test at the screening visit.

Exclusion criteria

  • Pregnancy
  • Initiation of a drug known to cause or exacerbate psoriasis
  • Having received an investigational medical product (IMP) or investigational device within 28 days' prior randomization
  • Alcohol and drug abuse or any condition associated with poor compliance
  • Malabsorption disorder
  • Scheduled hospitalization during the course of the study that could compromise the study
  • Major diseases or infections
  • Known or suspected sensitivity or allergic reactions to the IMP or excipients
  • Presence of other major medical or psychiatric illness that would affect the ability to participate in the study or put the subject at increased risk
  • Planned trip abroad to a sunny resort involving active sun exposure
  • Any anti psoriatic treatment
  • Immunosuppressive - immunomodulating treatment given for any other reason than psoriasis
  • UV treatment and return from a sunny resort involving active sun exposure for the last 4-6 weeks

Treatment and study plan

Psorax35

Dietary Supplement

This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.

MCT oil

Dietary Supplement

This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.

Primary outcomes

  1. Change in PASI

    Time frame: Baseline to 32 weeks

    Change from baseline in PASI in the Psorax35 group as compared to Placebo at week 32.

Secondary outcomes

  1. Change in PASI over 24 weeks

    Time frame: Baseline to 24 weeks

    Change from baseline in PASI in the Psorax35 group as compared to Placebo at week 6, 12, 18, and 24.

  2. Number of patients achieving PASI<3

    Time frame: Baseline to 32 weeks

    Number of patients achieving PASI<3 in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.

  3. Improvement in PASI

    Time frame: Baseline to 32 weeks

    Difference in 50% improvement in PASI (PASI-50), difference in 75% improvement in PASI (PASI-75) and difference in 90% improvement in PASI (PASI-90) from baseline in the Psorax35 group as compared with Placebo group at week 6, 12, 18, 24, and 32.

  4. Change in Physician's Static Global Assessment (PSGA)

    Time frame: Baseline to 32 weeks

    Changes from baseline in PSGA=0-1 demonstrating clear or almost clear skin in the Psorax35 group as compared to Placebo group at week 6, 12, 18, 24, and 32.

  5. Change in Dermatology Life Quality Index (DLQI)

    Time frame: Baseline to 32 weeks

    Changes from baseline in DLQ index in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.

  6. Change in EuroQoL 5 index (EQ-5D)

    Time frame: Baseline to 32 weeks

    Change from baseline in EuroQoL 5 index in the Psorax35 group as compared to Placebo group at week 6, 12, 18, 24, and 32.

  7. Change in Visual analogue scale (VAS) score

    Time frame: Baseline to 32 weeks

    Changes from baseline in VAS Scores (pruritus, pain skin/joints, stinging and total health condition (general/skin)) in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.

  8. Changes in highly sensitive C-reactive protein

    Time frame: Baseline to 32 weeks

    Changes from baseline in highly sensitive C-reactive protein (mg/L) in the Psorax35 group as compared to Placebo at week 12, and 32.

  9. Adverse Events (AE) and Severe Adverse Events (SAE)

    Time frame: Baseline to week 32

    Monitoring of AEs and SAEs.

  10. Changes in fasting serum lipids

    Time frame: Baseline to 32 weeks

    Changes from baseline in serum lipids (Triacylglycerol (TAG), total cholesterol (TK), HDL-cholesterol, LDL-cholesterol, free-cholesterol, phospholipids, non-esterified fatty acids, non-HDL-cholesterol - mmol/L) and lipid ratios (TAG/TK ratio, HDL-chol/LDL-chol ratio), in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.

  11. Changes in fasting serum glucose

    Time frame: Baseline to 32 weeks

    Changes from baseline in serum glucose (mmol/L) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32

  12. Changes in fasting serum insulin and insulin C-peptide

    Time frame: Baseline to 32 weeks

    Changes from baseline in serum insulin (mIE/L) and insulin C-peptide (nmol/L) in the Psorax35 group as compared to Placebo at week 12, and 32.

  13. Changes in fasting serum HbA1c

    Time frame: Baseline to 32 weeks

    Changes from baseline in serum HbA1c (%) in the Psorax35 group as compared to Placebo at week 12, and 32.

  14. Changes in blood pressure

    Time frame: Baseline to 32 weeks

    Changes from baseline in blood pressure (mmHg) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.

  15. Changes in heart rate

    Time frame: Baseline to 32 weeks

    Changes from baseline in heart rate (bpm) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.

  16. Changes in Body Mass Index (BMI)

    Time frame: Baseline to 32 weeks

    Changes from baseline in Body Mass Index (BMI) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.

    Weight in kilograms and height in meters will be combined to report BMI in kg/m2

  17. Changes in waist/hip ratio

    Time frame: Baseline to 32 weeks

    Changes from baseline in waist/hip ratio in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.

    Waist in centimeters and hip in centimeters will be combined to report waist/hip ratio.

  18. Changes in plasma cytokines including adipocytokines

    Time frame: Baseline to 32 weeks

    Changes from baseline in plasma cytokines including adipocytokines (pg/mL) in the Psorax35 group as compared to Placebo group at week 12, and 32.

  19. Changes in serum antioxidant capacity

    Time frame: Baseline to 32 weeks

    Changes from baseline in serum antioxidant capacity (nmol Trolox ekv./ul) in the Psorax35 group as compared to Placebo group at week 12, and 32.

  20. Changes in serum Vitamin D

    Time frame: Baseline to 32 weeks

    Changes from baseline in serum Vitamin D (nmol/L) in the psorax35 group as compared to Placebo group at week 12, and 32.

  21. Difference in use of cream-based treatment

    Time frame: Baseline to 32 weeks

    Difference in use of rescue medication from baseline in the Psorax35 group as compared to placebo group at week 6, 12, 18, 24, and 32.

    Amount of cream-based treatment in grams and number of days treated will be combined to report the use.

  22. Changes in safety laboratory parameters including hematology, clinical chemistry

    Time frame: Baseline to 32 weeks

    Changes from baseline in safety laboratory parameters including hematology (Hemoglobin-g/dL, Hematocrit, Erythrocytes-10^9/L, Leukocytes-10^9/L, Lymphocytes-10^9/L, Monocytes-10^9/L, Eosinophiles-10^9/L, Neutrophiles-10^9/L, Blood plates-10^9/L), and clinical chemistry (ALAT-u/L, lactate dehydrogenase-u/L, creatine kinase-u/L, creatinine-umol/L, gamma-glutamyltransferase-u/L).

Sponsors and collaborators

Lead sponsor

Arctic Nutrition AS

Industry

Collaborators

  • Haukeland University Hospital
  • University of Bergen

Registry information

Official study title

Randomized, Double Blind, Placebo Controlled Clinical Study to Investigate Efficacy of Psorax35 for Treatment of Psoriasis

Important dates

Study start
2017
Primary completion
2018
Study completion
2019
First posted
Dec 2, 2017
Registry last updated
Sep 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.